Citigroup’s Galmed Pharmaceuticals GLMD Stock Holding History

Citigroup’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3	Closed	-$3K	–	6013
2022 Q2	$3K	Buy	+3	New	+$3.98K	﹤0.01%	5773
2022 Q1	–	Hold	0	–	–	–	6164
2015 Q3	–	Hold	0	–	–	–	7500
2015 Q2	–	Hold	0	–	–	–	7599
2015 Q1	–	Hold	0	–	–	–	7272
2014 Q4	–	Sell	-1	Closed	-$8.69K	–	7186
2014 Q3	$7K	Buy	+1	New	+$10.9K	﹤0.01%	6418
2014 Q2	–	Hold	0	–	–	–	6456

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

WWM

Western Wealth Management Golden, Colorado $3.06B AUM 26.31% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citigroup's GLMD Position: Q3 2022 in Review

Citigroup sold out of Galmed Pharmaceuticals (GLMD) in Q3 2022, closing a stake of 3 shares — an estimated $3K sold.

Citigroup first reported a position in GLMD in Q3 2014 and held it in 2 quarters. The position peaked at $7K in Q3 2014. 24 funds tracked by Wall St. Rank hold GLMD as of Q3 2022.

Citigroup reported no remaining Galmed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Citigroup sold 3 Galmed Pharmaceuticals shares in Q3 2022, an estimated $3K.
Citigroup first reported a position in Galmed Pharmaceuticals in Q3 2014 and held it in 2 quarters.
Citigroup's Galmed Pharmaceuticals position peaked at $7K in Q3 2014.
24 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.